Apoptotic Signaling Pathways in Rats With Endometrial Hyperplasia
NCT ID: NCT02872818
Last Updated: 2016-08-23
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE4
40 participants
INTERVENTIONAL
2014-10-31
2015-03-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Intravaginal Misoprostol Versus Dinoprostone Before Diagnostik Hysteroscopy
NCT01620814
Rectal Misoprostol Versus Sublingual Misoprostol Prior to Myomectomy
NCT02716142
Comparison Effectiveness of Rectal Misoprostol & Intravenous Tranexamic Acid Reducing Hemorrhage in Myomectomy
NCT06114758
Impact of Misoprostol on Blood Loss In Myomectomy Operations
NCT02061657
Preoperative Vaginal Dinoprostone Versus Misoprostone in Abdominal Myomectomy
NCT05761418
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
TRIPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Control group
Medicated with only 4mg/kg 17β estradiol hemihydrate for 20 days to develop endometrial hyperplasia
17β estradiol hemihydrate
4mg/kg/day for 20 days
Metformin group
Having been obtained hyperplasia, the investigators continued medication with 50 mg/kg metformin in addition to 17β estradiol hemihydrate for 10 days
17β estradiol hemihydrate
4mg/kg/day for 20 days
Metformin
50 mg/kg/day last 10 days
Medroxyprogesterone acetate group
Having been obtained hyperplasia, the investigators continued medication with 1mg/day medroxyprogesterone acetate in addition to 17β estradiol hemihydrate for 10 days
17β estradiol hemihydrate
4mg/kg/day for 20 days
medroxyprogesterone acetate
1mg/kg/day last 10 days
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
17β estradiol hemihydrate
4mg/kg/day for 20 days
Metformin
50 mg/kg/day last 10 days
medroxyprogesterone acetate
1mg/kg/day last 10 days
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
8 Weeks
10 Weeks
FEMALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Kayseri Education and Research Hospital
OTHER_GOV
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Erdem Sahin
Principal Investigator
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Erdem SAHİN
Role: STUDY_DIRECTOR
Kayseri Training and Research Hospital
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Kayseri Training and Research Hospital
Kayseri, , Turkey (Türkiye)
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
14/128
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.